K 305 20 June 03 03/06/20 1.

Slides:

Advertisements

Similar presentations

Robert M. Guthrie, MD Professor of Emergency Medicine

Advertisements

ATP III Guidelines Specific Dyslipidemias. 2 Specific Dyslipidemias: Very High LDL Cholesterol (  190 mg/dL) Causes and Diagnosis Genetic disorders –Monogenic.

Plant stanol ester in the treatment and prevention guidelines 0.

Journal Reading Myocardial infarction in young people Cardiol J 2009; 16, 4: 307–311 Cardiol J 2008; 15: 21–25 Presented by R 王郁菁 at ER conference.

Chapter 5 Human Heredity by Michael Cummings ©2006 Brooks/Cole-Thomson Learning Concordance When both twins express the same trait.

Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?

Cardiovascular Disease in Women Module III: Risk Assessment Tool.

Continuing Medical Education Programs Dr. Anika Niambi Al-Shura, Lecturer Copyright 2014 Niambi Wellness. All rights reserved.

Hyperlipidemia John Baer.

AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.

Staying Healthy Kim F Gibson, MD, FACP NNMC Bethesda The Key to Your Heart.

Staying Healthy Kim F Gibson, MD, FACP NNMC Bethesda The Key to Your Heart.

03/06/231 K June /06/232 Atherosclerosis Etiology Classic Risk Factors Dyslipidemia Low HDL Epidemiological Studies (e.g. Framingham) Genetic.

WELCOME !. ABOUT PCNA PCNA is the leading nursing organization dedicated to preventing cardiovascular disease through assessing risk, facilitating lifestyle.

Cardiovascular Disease. Caused by Atherosclerosis  Blocked artery By plaque Arteriosclerosis  “Hardening of the arteries”

Prepared by: ABDULAZIZ ALESSA ABDULAZIZ ALESSA

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

Cardiovascular Disease. Caused by Atherosclerosis –Blocked artery By plaque Arteriosclerosis –“Hardening of the arteries”

Nutrigenomics KNH 413.

Dyslipidemia CASE 5A. Aling D., 62 years old female who came in for a General Check-up General Data.

Size and apolipoprotein composition are the main factors determining atherogenicity of triglyceride-rich particles.

HANDBOOK OF DYSLIPIDEMIA AND ATHEROSCLEROSIS Part One Professor Jean-Charles Fruchart Department of Atherosclerosis (Inserm UR545) Pasteur Institute of.

What do I remember? What is thrombosis?

Prophylaxis of Coronary Heart Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels.

CLASSIFICATION OF HYPERLIPIDEMIA Presented By : Moaath A. Alsheikh Medical

Dufaux, International Journal of Sports Medicine, 1982 TRIGLYCERIDES & TRAINING Increase Decrease No Change Numbers of Studies.

FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Cardiovascular Disease

Arabinda Mohan Bhattarai, MBBS, MD (Biochemistry) Asst Prof, NAIHS

Copyright © 2017 American Academy of Pediatrics.

LIPID PROFILE OF EARLY RHEUMATOID ARTHRITIS PATIENTS

“Directionality” issues can be complex Cardiovascular Disease Clonal Hematopoiesis Age Smoking Obesity/Diabetes Hypertension Dyslipidemia Heritable Risk.

The effects of apo E alleles on various lipoprotein parameters

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2012 American Medical Association. All rights reserved.

Lipoprotein(a), Cardiovascular Disease, and Contemporary Management

What is the likely mechanism by which HDL-C reduces coronary heart disease?

Genes and environment in type 2 diabetes and atherosclerosis

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

Nutrigenomics KNH 413.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Shedding Light on HDL: Myths and Controversies

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Volume 79, Issue 9, Pages (May 2011)

62-year-old Man With Unstable Angina

Type 2 diabetes: Overlap of clinical conditions

Nutrigenomics KNH 413.

Nutrigenomics KNH 413.

Nutrigenomics KNH 413.

بسم الله الرحمن الرحیم A Dynamical Model of Lipoprotein Metabolism

Interaction of hypercholesterolemia and inflammation in atherogenesis

SLE and Cardiovascular Risk

Advances in Hypertriglyceridemia Treatment

Rational Order of Laboratory Tests in Cardiovascular Diseases

Lipids & Lipoproteins Part 2 Lecture 13.

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Section overview: Cardiometabolic risk reduction

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk Terry.

Cardiovascular Disease in Women Module III: Risk Assessment Tool

Nutrigenomics KNH 413.

Nutrigenomics KNH 413.

Nutrigenomics KNH 413.

Amir A. Mahabadi et al. JIMG 2017;10:

III. Treating dyslipidemias

Specific Dyslipidemias: Very High LDL Cholesterol (>190 mg/dL)

Presentation transcript:

K 305 20 June 03 03/06/20 1

Cardiovascular Adaptations to Exercise Acute Chronic (Training) 03/06/20 1

03/06/20 1

Atherosclerosis Definition CV Effects Etiology Classic Risk Factors 03/06/20 1

03/06/20 1

Atherosclerosis Etiology Classic Risk Factors Dyslipidemia Elevated LDL and TG Epidemiological Studies (e.g. Framingham) Pharmacological Studies (e.g. statins) Genetic Disorders Familial Hypercholesterolemia Genetic Models Apolipoprotein E (apo E) KO 03/06/20 1

03/06/20 1

Atherosclerosis Etiology Classic Risk Factors Dyslipidemia Low HDL Epidemiological Studies (e.g. Framingham) Genetic Disorders Tangier Disease 03/06/20 1

03/06/20 1